Breast MRI during workup of DCIS can spur anxiety in women
Women undergoing breast MRI for evaluation of ductal carcinoma in situ experienc...Read more on AuntMinnie.comRelated Reading:
Contrast-enhanced mammography can predict underestimated DCIS
Prediction models can reduce false positives in breast MRI screening
DCIS shows as nonmass enhancement on breast MRI
Health practitioners overestimate likelihood of disease, study says
Women with DCIS have 3x the risk of breast cancer death (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2021 Category: Radiology Source Type: news
Sharing Mayo Clinic: 'Sneaky' cancer spurs mom and daughter to action
When Lisa Pitre, a Mayo Clinic speech pathologist from Jacksonville, Florida, went in for a routine mammogram in summer 2019, nothing on her imaging was concerning. By October, though, Lisa was diagnosed with stage 4 invasive lobular carcinoma, an aggressive type of breast cancer. "I learned that 20% of breast cancers are not detected on mammograms, and mine was one of those," says the 53-year-old mother of two, noting that her cancer was found only after an MRI… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 30, 2021 Category: Databases & Libraries Source Type: news
Bringing WISDOM to Breast Cancer Care
Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - October 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Quality of Anatomic Staging of Breast Carcinoma Quality of Anatomic Staging of Breast Carcinoma
By comparing pathologic and clinical staging data, this study aimed to assess the accuracy of clinical breast cancer anatomic staging at US hospitals.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
PET recommended over bone scintigraphy in pediatric sarcoma
PET imaging is more effective than bone scintigraphy for detecting metastati...Read more on AuntMinnie.comRelated Reading:
Body position on x-ray affects radiation dose in children
Deep learning classifies brain tumors on single MRI scans
AI can identify hepatocellular carcinoma on liver CT exams
Black women less likely to receive breast surgery follow-up
MRI offers kids radiation-free chemo response tracking (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 13, 2021 Category: Radiology Source Type: news
DCIS shows as nonmass enhancement on breast MRI
Ductal carcinoma in situ (DCIS) diagnosed with conventional breast imaging usuall...Read more on AuntMinnie.comRelated Reading:
Contrast mammography plus ultrasound on par with MRI for preop staging
Out-of-pocket costs may block women from breast MRI
Researchers tout algorithm in classifying breast tissues
AI detects axillary lymph node metastasis on multiparametric MRI
Abbreviated breast MRI bests mammo, ultrasound for 2nd cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 6, 2021 Category: Radiology Source Type: news
Coffee protects against liver cancer while alcohol is linked with numerous cancers
Alcohol consumption is a major risk factor for several cancers including head & neck (mouth, pharynx, larynx), oesophageal and bowel cancer - as well as the more widely known links to breast and liver cancer - according to a new study funded by World Cancer Research Fund (WCRF)(1), and published this week in Nature Communications. The study also found increased coffee consumption was associated with a lower risk of developing liver cancer and basal cell carcinoma of the skin. (Source: World Pharma News)
Source: World Pharma News - August 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective ...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news
US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective ...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news
Biocon Biologics, Viatris receive approval for cancer drug
Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 26, 2021 Category: Pharmaceuticals Source Type: news
Surgical technique may reduce positive margin rate in breast cancer patients with DCIS
(Wake Forest Baptist Medical Center) According to the American Cancer Society, a noninvasive breast cancer called ductal carcinoma in situ (DCIS) accounts for approximately one of every four new breast cancer cases in the United States. If left untreated, DCIS has the potential to evolve into invasive cancer, so many patients choose to have breast-conserving surgery or mastectomy after a diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 5, 2021 Category: Cancer & Oncology Source Type: news